Imc-Chicago Adds $9M in ABIVAX Société Anonyme ($ABVX)
Key Points
- Imc-Chicago changed its ABIVAX Société Anonyme ($ABVX) stake by 542.6% last quarter, boosting to 106,143 shares worth $10.45 million.
- Wall Street's consensus rating on $ABVX is Buy and an average price target of $149.09.
- $ABVX last traded around $98.44.
Imc-Chicago increased its position in ABIVAX Société Anonyme ($ABVX) by 542.6% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 106,143 shares of ABIVAX Société Anonyme after buying 89,624 shares during the quarter. Imc-Chicago's holdings in ABIVAX Société Anonyme were worth $10.45 million as of its most recent filing.
ABIVAX Société Anonyme ($ABVX) Stock
ABIVAX Société Anonyme Earnings
Analysts Set New Price Targets
About ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.